Curated News
By: NewsRamp Editorial Staff
May 08, 2025
Clene Announces Q1 2025 Financial Results and Progress on CNM-Au8 Program for ALS and MS
TLDR
- Clene announced progress on its CNM-Au8 program for ALS and MS, preparing for potential NDA submission, giving a competitive edge in the market.
- CNM-Au8 improves survival and function in CNS cells by targeting mitochondrial function, NAD pathway, and reducing oxidative stress, supporting neurodegenerative disease treatment.
- Clene's CNM-Au8 program shows significant survival improvement in severe ALS patients and Phase 2 results demonstrating remyelination and neuronal repair in MS, offering hope for better treatments.
- Clene's new data demonstrates exciting advancements in improving survival for ALS patients and promoting neuronal repair in MS, showcasing cutting-edge research in neurodegenerative disease treatment.
Impact - Why it Matters
This news matters as Clene's advancements in developing therapies for neurodegenerative diseases like ALS and MS could potentially lead to improved treatment options for patients. The company's progress towards potential FDA approval and positive clinical trial results signify a significant step forward in the field of neurodegenerative disease research.
Summary
Clene (NASDAQ: CLNN) announced first quarter 2025 financial results and progress on its CNM-Au8 program for ALS and MS. The company is preparing for a potential NDA submission under the FDA’s Accelerated Approval pathway for ALS in Q4 2025, supported by survival data and upcoming biomarker analysis. New data also showed CNM-Au8 significantly improved survival in patients with more severe ALS. In MS, Clene presented Phase 2 extension results demonstrating remyelination and neuronal repair. The company reported a Q1 net loss of $0.8 million on reduced expenses and $9.8 million in cash, funding operations into Q3 2025.
For more information, view the full press release here.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Clene Announces Q1 2025 Financial Results and Progress on CNM-Au8 Program for ALS and MS
